Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia

Key Points

• The primary aim is to assess the antipsychotic effects of the PDE10A inhibitor MK-8189 in individuals experiencing acute schizophrenia.
• Conducted a Phase 2b clinical trial
• Evaluated the effects of MK-8189 at specific doses
• Focused on individuals with acute episodes of schizophrenia
• No significant antipsychotic effects were observed at the tested doses
• Findings suggest that PDE10A inhibition may not be beneficial in this context